nicotinic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
nicotinic acid or nicotinoyl alcohol derivatives	2835	59-67-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: niacin potassium niacin magnesium nicotinic acid vitamin b3 (niacin) 3-pyridinecarboxylic acid niaspan niacin niacor Vitamin B3	A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties. Molecular weight: 123.11 Formula: C6H5NO2 CLOGP: 0.80 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 50.19 ALOGS: -0.17 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

niacin potassium
niacin magnesium
nicotinic acid
vitamin b3 (niacin)
3-pyridinecarboxylic acid
niaspan
niacin
niacor
Vitamin B3

A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

Molecular weight: 123.11
Formula: C6H5NO2
CLOGP: 0.80
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 50.19
ALOGS: -0.17
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O
0.20	g	P
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	16.66 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	101.53 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
July 24, 1957	FDA	MEDPOINTE PHARM HLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Flushing	460.48	12.94	263	14304	69837	56207663
Drug hypersensitivity	207.36	12.94	302	14265	274903	56002597
Skin burning sensation	122.65	12.94	59	14508	10972	56266528
Pruritus	115.20	12.94	253	14314	316370	55961130
Paraesthesia	49.19	12.94	106	14461	130408	56147092
Product residue present	47.40	12.94	22	14545	3773	56273727
Myalgia	43.89	12.94	102	14465	131923	56145577
Feeling hot	43.72	12.94	54	14513	41733	56235767
Erythema	42.86	12.94	112	14455	155827	56121673
Urticaria	41.92	12.94	106	14461	144570	56132930
Rheumatoid arthritis	41.19	12.94	24	14543	382580	55894920
Infusion related reaction	37.25	12.94	5	14562	208926	56068574
Rhabdomyolysis	36.96	12.94	49	14518	40609	56236891
Burning sensation	31.56	12.94	50	14517	48646	56228854
Blood triglycerides increased	30.87	12.94	25	14542	11652	56265848
Discoloured vomit	29.32	12.94	10	14557	763	56276737
Systemic lupus erythematosus	28.36	12.94	6	14561	180072	56097428
Coronary artery disease	27.81	12.94	37	14530	30759	56246741
Femoral artery dissection	26.58	12.94	5	14562	30	56277470
Glossodynia	26.34	12.94	4	14563	152454	56125046
Low density lipoprotein increased	25.57	12.94	17	14550	5857	56271643
Sinoatrial block	24.67	12.94	9	14558	837	56276663
Off label use	24.39	12.94	69	14498	556111	55721389
Drug ineffective	22.91	12.94	142	14425	918847	55358653
Blood glucose increased	20.64	12.94	54	14513	75097	56202403
Maternal exposure during pregnancy	20.20	12.94	12	14555	189541	56087959
Completed suicide	19.99	12.94	5	14562	133828	56143672
Lower respiratory tract infection	19.85	12.94	3	14564	114791	56162709
Myopathy	19.80	12.94	18	14549	9794	56267706
Treatment failure	19.30	12.94	10	14557	170382	56107118
Wound	19.21	12.94	6	14561	138798	56138702
Neutropenia	18.33	12.94	9	14558	158158	56119342
Blood cholesterol abnormal	18.03	12.94	10	14557	2490	56275010
General physical health deterioration	17.78	12.94	11	14556	169999	56107501
Cyst	17.54	12.94	19	14548	12759	56264741
Pyrexia	16.86	12.94	54	14513	418719	55858781
Stress	15.83	12.94	42	14525	58868	56218632
Febrile neutropenia	15.65	12.94	4	14563	105541	56171959
High density lipoprotein decreased	15.38	12.94	8	14559	1754	56275746
Hyperlipidaemia	15.19	12.94	21	14546	18088	56259412
Swelling face	15.10	12.94	40	14527	56029	56221471
Condition aggravated	14.92	12.94	43	14524	344855	55932645
Internal haemorrhage	14.31	12.94	11	14556	4753	56272747
Blood magnesium increased	13.97	12.94	9	14558	2942	56274558
Bicytopenia	13.94	12.94	8	14559	2125	56275375
Low turnover osteopathy	13.70	12.94	10	14557	3998	56273502
Chest pain	13.68	12.94	90	14477	189707	56087793
Product use in unapproved indication	13.53	12.94	10	14557	140812	56136688
Angina pectoris	13.23	12.94	25	14542	27951	56249549
Pain in extremity	13.16	12.94	126	14441	297305	55980195

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Flushing	920.30	12.96	422	19047	29706	31648169
Product residue present	230.07	12.96	79	19390	2551	31675324
Pruritus	115.40	12.96	244	19225	124923	31552952
High density lipoprotein decreased	108.13	12.96	48	19421	3102	31674773
Myalgia	93.49	12.96	169	19300	77089	31600786
Myocardial infarction	75.75	12.96	195	19274	113259	31564616
Skin burning sensation	74.67	12.96	40	19429	3899	31673976
Off label use	58.33	12.96	77	19392	347197	31330678
Drug hypersensitivity	57.14	12.96	133	19336	72466	31605409
Blood glucose increased	48.15	12.96	112	19357	60971	31616904
Feeling hot	47.25	12.96	54	19415	16179	31661696
Blood creatine phosphokinase increased	45.92	12.96	88	19381	41886	31635989
Toxicity to various agents	44.97	12.96	28	19441	181459	31496416
Coronary artery disease	44.85	12.96	92	19377	45995	31631880
Burning sensation	40.98	12.96	51	19418	16696	31661179
Blood triglycerides increased	39.72	12.96	45	19424	13352	31664523
Coronary artery occlusion	38.11	12.96	39	19430	10317	31667558
Paraesthesia	37.98	12.96	97	19372	55974	31621901
Respiratory tract infection bacterial	36.82	12.96	18	19451	1448	31676427
Low density lipoprotein increased	32.70	12.96	24	19445	4064	31673811
Respiratory tract infection viral	31.44	12.96	18	19451	1996	31675879
Rhabdomyolysis	31.31	12.96	98	19371	63483	31614392
Product use in unapproved indication	31.15	12.96	11	19458	99160	31578715
Febrile neutropenia	24.77	12.96	23	19446	121826	31556049
Completed suicide	24.22	12.96	13	19456	91501	31586374
Blood cholesterol increased	23.04	12.96	39	19430	16854	31661021
Dyspepsia	22.74	12.96	57	19412	32496	31645379
Injury	22.38	12.96	42	19427	19667	31658208
Product use issue	22.23	12.96	4	19465	56755	31621120
Erythema	21.44	12.96	102	19367	80303	31597572
Death	21.37	12.96	132	19337	360437	31317438
Dizziness	21.31	12.96	201	19268	198946	31478929
General physical health deterioration	21.24	12.96	23	19446	113412	31564463
Muscle spasms	20.70	12.96	90	19379	68228	31609647
Neutropenia	20.65	12.96	34	19435	140330	31537545
Myopathy	20.32	12.96	29	19440	10823	31667052
Hot flush	20.27	12.96	36	19433	16160	31661715
Transaminases abnormal	19.57	12.96	7	19462	255	31677620
Chest pain	17.86	12.96	128	19341	116829	31561046
Pain in extremity	16.50	12.96	125	19344	116078	31561797
Cerebrovascular accident	16.46	12.96	94	19375	79390	31598485
Asthenia	15.86	12.96	209	19260	224546	31453329
Foetal exposure during pregnancy	15.75	12.96	3	19466	40873	31637002
Treatment failure	15.70	12.96	3	19466	40789	31637086
Hypoaesthesia	15.61	12.96	72	19397	55950	31621925
Glycosylated haemoglobin increased	15.51	12.96	25	19444	10375	31667500
Gout	15.05	12.96	34	19435	18140	31659735
Angina pectoris	14.86	12.96	46	19423	29595	31648280
Impaired work ability	14.54	12.96	18	19451	5859	31672016
Urticaria	13.92	12.96	71	19398	57446	31620429
Blood testosterone decreased	13.78	12.96	15	19454	4258	31673617
Condition aggravated	13.76	12.96	53	19416	163956	31513919
Renal impairment	13.56	12.96	20	19449	86329	31591546
Cardiac failure	13.41	12.96	20	19449	85933	31591942
Flatulence	13.04	12.96	33	19436	18915	31658960
Gastrointestinal haemorrhage	12.97	12.96	91	19378	82458	31595417

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Flushing	194.02	11.78	182	22943	81990	70823329
Drug hypersensitivity	112.95	11.78	258	22867	262201	70643118
Myocardial infarction	102.31	11.78	193	22932	171452	70733867
Coronary artery disease	89.01	11.78	106	23019	62630	70842689
Myalgia	85.79	11.78	177	22948	167715	70737604
Rhabdomyolysis	71.61	11.78	119	23006	95641	70809678
High density lipoprotein decreased	58.40	11.78	28	23097	4091	70901228
Blood creatine phosphokinase increased	49.68	11.78	79	23046	61184	70844135
Off label use	49.05	11.78	106	23019	742954	70162365
Blood triglycerides increased	45.28	11.78	43	23082	19621	70885698
Respiratory tract infection bacterial	44.83	11.78	18	23107	1719	70903600
Rheumatoid arthritis	32.99	11.78	28	23097	291777	70613542
Respiratory tract infection viral	32.60	11.78	18	23107	3523	70901796
Coronary artery occlusion	32.32	11.78	31	23094	14314	70891005
Completed suicide	32.11	11.78	17	23108	227118	70678201
Contraindicated product administered	30.34	11.78	4	23121	134608	70770711
Myopathy	27.29	11.78	32	23093	18580	70886739
Blood glucose increased	26.66	11.78	84	23041	102898	70802421
Infusion related reaction	26.17	11.78	16	23109	197518	70707801
Angina pectoris	25.83	11.78	52	23073	48331	70856988
Low density lipoprotein increased	25.27	11.78	21	23104	8044	70897275
Product use in unapproved indication	24.57	11.78	19	23106	207459	70697860
Femoral artery dissection	24.28	11.78	5	23120	39	70905280
Febrile neutropenia	23.83	11.78	19	23106	204299	70701020
Cerebrovascular accident	22.06	11.78	99	23026	143371	70761948
Discoloured vomit	22.03	11.78	10	23115	1291	70904028
Cardiac failure congestive	21.99	11.78	95	23030	135362	70769957
General physical health deterioration	21.73	11.78	27	23098	236004	70669315
Treatment failure	21.55	11.78	10	23115	144132	70761187
Acute myocardial infarction	21.25	11.78	62	23063	72825	70832494
Toxicity to various agents	20.85	11.78	60	23065	382112	70523207
Product residue present	20.22	11.78	13	23112	3357	70901962
Chest pain	19.23	11.78	144	22981	251116	70654203
Sinoatrial block	19.15	11.78	9	23116	1257	70904062
Therapy cessation	18.95	11.78	37	23088	33639	70871680
Maternal exposure during pregnancy	18.86	11.78	7	23118	115338	70789981
Glycosylated haemoglobin increased	17.77	11.78	25	23100	17366	70887953
Dizziness	17.75	11.78	230	22895	463911	70441408
Gastrointestinal haemorrhage	17.63	11.78	90	23035	137318	70768001
Condition aggravated	17.40	11.78	76	23049	427559	70477760
Systemic lupus erythematosus	16.97	11.78	6	23119	101896	70803423
Hyperlipidaemia	16.95	11.78	29	23096	23834	70881485
Neutropenia	16.62	11.78	37	23088	257119	70648200
Blood testosterone decreased	16.60	11.78	10	23115	2303	70903016
Angina unstable	16.47	11.78	23	23102	15870	70889449
Lower respiratory tract infection	16.37	11.78	8	23117	111905	70793414
Transaminases abnormal	16.36	11.78	7	23118	785	70904534
Burning sensation	15.44	11.78	45	23080	52825	70852494
Product use issue	15.12	11.78	22	23103	179915	70725404
Drug intolerance	14.97	11.78	32	23093	225655	70679664
International normalised ratio increased	14.97	11.78	59	23066	80667	70824652
Urticaria	14.54	11.78	97	23028	162952	70742367
Blood cholesterol abnormal	14.08	11.78	10	23115	3038	70902281
Muscle spasms	13.95	11.78	92	23033	153954	70751365
Metabolic syndrome	13.51	11.78	9	23116	2466	70902853
Dyspnoea exertional	13.49	11.78	56	23069	78374	70826945
Oedema peripheral	13.31	11.78	123	23002	227968	70677351
Pericardial haemorrhage	13.14	11.78	11	23114	4257	70901062
Pruritus	13.09	11.78	171	22954	345389	70559930
Drug ineffective	13.02	11.78	222	22903	939530	69965789
Coronary artery restenosis	12.99	11.78	7	23118	1305	70904014
Skin burning sensation	12.54	11.78	17	23108	11409	70893910
Pyrexia	12.13	11.78	133	22992	606819	70298500
Paraesthesia	12.03	11.78	85	23040	145452	70759867
Arteriosclerosis coronary artery	11.90	11.78	20	23105	16195	70889124

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C04AC01	CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS PERIPHERAL VASODILATORS Nicotinic acid and derivatives
ATC	C10AD02	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Nicotinic acid and derivatives
ATC	C10AD52	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Nicotinic acid and derivatives
ATC	C10BA01	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
FDA CS	M0014839	Nicotinic Acids
FDA EPC	N0000175594	Nicotinic Acid
MeSH PA	D000963	Antimetabolites
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents
MeSH PA	D018977	Micronutrients
MeSH PA	D014665	Vasodilator Agents
MeSH PA	D014803	Vitamin B Complex
MeSH PA	D014815	Vitamins
CHEBI has role	CHEBI:25212	metabolites
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35679	antilipemic drugs
CHEBI has role	CHEBI:50247	antidotes
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:84087	human urinary metabolites
CHEBI has role	CHEBI:84264	nicotinamide deaminase inhibitors
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:23357	cofactor
CHEBI has role	CHEBI:61115	histone deacetylase inhibitors
CHEBI has role	CHEBI:62913	PARP
CHEBI has role	CHEBI:63726	neuroprotective agents
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:71181	Sir2 inhibitors
CHEBI has role	CHEBI:75772	S. cerevisiae metabolites
CHEBI has role	CHEBI:176497	geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Hyperlipidemia	indication	55822004	DOID:1168
Vitamin deficiency	indication	85670002
Familial hypercholesterolemia - heterozygous	indication	238079002
Mixed hyperlipidemia	indication	267434003
Hypertriglyceridemia	indication	302870006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.31	acidic
pKa2	4.85	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Hydroxycarboxylic acid receptor 2	GPCR	Q8TDS4	HCAR2_HUMAN	AGONIST	Ki	7.30	CHEMBL	SCIENTIFIC LITERATURE
Nicotinamide N-methyltransferase	Enzyme	P40261	NNMT_HUMAN				WOMBAT-PK
Nicotinate-nucleotide pyrophosphorylase [carboxylating]	Enzyme	Q15274	NADC_HUMAN				WOMBAT-PK
Nicotinamide phosphoribosyltransferase	Enzyme	P43490	NAMPT_HUMAN				WOMBAT-PK
Hydroxycarboxylic acid receptor 3	GPCR	P49019	HCAR3_HUMAN	AGONIST	EC50	6.52	IUPHAR
Amyloid beta A4 protein	Unclassified	P05067	A4_HUMAN		IC50	4.88	CHEMBL
Hydroxycarboxylic acid receptor 2	GPCR		HCAR2_MOUSE		IC50	6.85	CHEMBL
Hydroxycarboxylic acid receptor 2	GPCR		HCAR2_RAT		Ki	7.48	CHEMBL

External reference:

ID	Source
4019440	VUID
N0000147570	NUI
D00049	KEGG_DRUG
4017632	VANDF
4017661	VANDF
4017718	VANDF
4019440	VANDF
4020285	VANDF
4021898	VANDF
C0027996	UMLSCUI
CHEBI:15940	CHEBI
NIO	PDB_CHEM_ID
CHEMBL573	ChEMBL_ID
938	PUBCHEM_CID
DB00627	DRUGBANK_ID
1588	IUPHAR_LIGAND_ID
218728	RXNORM
2275	MMSL
4947	MMSL
5169	MMSL
5170	MMSL
5684	MMSL
7159	MMSL
7161	MMSL
72420	MMSL
d00314	MMSL
d03739	MMSL
001052	NDDF
001055	NDDF
173196005	SNOMEDCT_US
273943001	SNOMEDCT_US
63639004	SNOMEDCT_US
D009525	MESH_DESCRIPTOR_UI
373	INN_ID
2679MF687A	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3074	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3074	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3079	TABLET, FILM COATED, EXTENDED RELEASE	750 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3079	TABLET, FILM COATED, EXTENDED RELEASE	750 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3080	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3080	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3265	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3265	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3274	TABLET, FILM COATED, EXTENDED RELEASE	750 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3274	TABLET, FILM COATED, EXTENDED RELEASE	750 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3275	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	NDA	29 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	0074-3275	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	NDA	29 sections
VitafolOne	HUMAN PRESCRIPTION DRUG LABEL	16	0642-0070	CAPSULE, GELATIN COATED	15 mg	ORAL	unapproved drug other	14 sections
Vitafol Caplet	HUMAN PRESCRIPTION DRUG LABEL	12	0642-0072	CAPSULE	15 mg	ORAL	UNAPPROVED DRUG OTHER	13 sections
Select OB	HUMAN PRESCRIPTION DRUG LABEL	15	0642-0077	TABLET, CHEWABLE	15 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
Vitafol OB Caplet	HUMAN PRESCRIPTION DRUG LABEL	15	0642-0079	TABLET	18 mg	ORAL	Unapproved drug other	14 sections
Vitafol Plus	HUMAN PRESCRIPTION DRUG LABEL	17	0642-0092	CAPSULE, LIQUID FILLED	15 mg	ORAL	UNAPPROVED DRUG OTHER	13 sections
Strovite Forte Caplet	HUMAN PRESCRIPTION DRUG LABEL	19	0642-0204	TABLET, COATED	100 mg	ORAL	UNAPPROVED DRUG OTHER	15 sections
Reaphirm Plant Source DHA	HUMAN PRESCRIPTION DRUG LABEL	16	0642-3010	CAPSULE, GELATIN COATED	15 mg	ORAL	unapproved drug other	7 sections
O-Cal Prenatal Vitamin	HUMAN PRESCRIPTION DRUG LABEL	16	0813-0202	TABLET	17 mg	ORAL	UNAPPROVED DRUG OTHER	6 sections
Niacin	HUMAN PRESCRIPTION DRUG LABEL	1	10135-612	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections
Niacin	HUMAN PRESCRIPTION DRUG LABEL	1	10135-613	TABLET, EXTENDED RELEASE	750 mg	ORAL	ANDA	25 sections
Niacin	HUMAN PRESCRIPTION DRUG LABEL	1	10135-614	TABLET, EXTENDED RELEASE	1000 mg	ORAL	ANDA	25 sections
TriStart DHA	HUMAN PRESCRIPTION DRUG LABEL	15	15370-250	CAPSULE, LIQUID FILLED	5 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	21695-852	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	NDA	26 sections
Niaspan	HUMAN PRESCRIPTION DRUG LABEL	1	21695-865	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	NDA	26 sections
Niacin	Human Prescription Drug Label	1	33342-187	TABLET	500 mg	ORAL	ANDA	25 sections
Niacin	Human Prescription Drug Label	1	33342-189	TABLET	1000 mg	ORAL	ANDA	25 sections
NIACIN	Human Prescription Drug Label	1	47335-539	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
NIACIN	Human Prescription Drug Label	1	47335-539	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections